Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07204340 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TLN-372 in Advanced KRAS Mutant Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment increased: 240 → 270 participantsv6
  2. Study sites: 10 to 11v5
  3. Study sites: 7 to 10v4
  4. Study sites: 6 to 7v3
  5. Study sites: 3 to 6 Start date changed from estimate of Oct 9, 2025 to Sep 29, 2025v2 Show 1 more changeShow less
    • Start date changed from estimate of Oct 9, 2025 to Sep 29, 2025
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors
Trial Details
NCT Number NCT07204340
Lead Sponsor Treeline Biosciences, Inc.
Conditions KRAS Mutant Solid Tumors
Enrollment 270 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov